Clinical Trials Browser

Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Pituitary Neoplasms, Prolactinoma, Central Nervous System Neoplasms, Growth Hormone-Secreting Pituitary Adenoma

NCT04335357 2020-04-06

TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas

Phase 2 Unknown

150 enrolled

Endocrine

Pituitary Neoplasms

NCT00939523 2020-01-22

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Phase 2 Completed

9 enrolled 11 charts

Endocrine

Pituitary Neoplasms, Prolactinoma

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Phase 2 Completed

33 enrolled 24 charts

Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT01966809 2019-08-20

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

Phase 2 Terminated

1 enrolled 5 charts

CNSEndocrineSarcoma

Astrocytoma, Brain Neoplasms, Chordoma, Craniopharyngioma, Glioblastoma, Glioma, Meningioma, Neoplasms, Germ Cell and Embryonal, Oligodendroglioma, Pituitary Neoplasms, Germinoma, Optic Nerve Glioma

NCT00054756 2018-08-08

Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities

Phase 2 Completed

96 enrolled 6 charts

EndocrineHead & Neck

Hypothyroidism, Pituitary Diseases, Pituitary Neoplasms, Thyroid Diseases

NCT00929669 2017-11-28

LAR

Phase 2 Terminated

2 enrolled 3 charts

Endocrine

Pituitary Neoplasms

NCT01849484 2016-08-01

HIPPO-SPARE 01

Phase 2 Unknown

150 enrolled

CNSEndocrineThoracic

Brain Neoplasms, Meningioma, Pituitary Neoplasms, Small Cell Lung Carcinoma

NCT00958841 2016-07-26

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Phase 2 Terminated

118 enrolled 11 charts

EndocrineGastrointestinal

ACTH Syndrome, Ectopic, Nelson Syndrome, Pancreatic Neoplasms, Pituitary Neoplasms, Neuroectodermal Tumors, Primitive

NCT01203618 2013-11-04

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Phase 2 Withdrawn

Endocrine

Pituitary Neoplasms

NCT00003514 2013-07-10

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Phase 2 Withdrawn

DermatologicEndocrine

Pituitary Neoplasms, Somatostatinoma, Carcinoma, Merkel Cell, Carcinoma, Islet Cell, Carcinoma, Neuroendocrine, Growth Hormone-Secreting Pituitary Adenoma

NCT00001860 2008-03-04

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

Phase 2 Completed

5 enrolled

Endocrine

Acromegaly, Pituitary Neoplasms

Clinical Trials

Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors

Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors

TMZ-Cap

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

PASSILCORT

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

Rosiglitazone in Treating Patients With Pituitary Tumors

Temozolomide in Treating Patients With Invasive Pituitary Tumors

TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas

Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities

LAR

HIPPO-SPARE 01

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly